drugset / Trial / NCT04796688
Universal Chimeric Antigen Receptor-modified AT19 Cells for CD19+ Relapsed/Refractory Hematological Malignancies
Phase 1
Unknown
27 enrolled
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Chengdu USino Technology Biology Co., Ltd · collab
NaSingle-groupOpen-labelTreatment
Summary
This is a single-center, open-label, single-arm study to evaluate the primary safety and efficacy of universal chimeric antigen receptor-modified AT19 cells in patients with relapsed or refractory hematological malignancies.
Timeline
- Start
- 2021-03-10
- Primary completion
- 2023-03-10
- Completion
- 2024-03-10
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | AT19 cells | Cell therapy | 5e+06 cells | — |
| Subject | AT19 cells | Cell therapy | 1e+07 cells | — |
| Subject | AT19 cells | Cell therapy | 2e+07 cells | — |
| Background | Cyclophosphamide | Other / unclassified | 300 mg/kg | — |
| Background | Fludarabine | Small molecule | 30 mg/kg | — |